Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Gonadorelin and Melanotan I — mechanism, side effects, legal status, and pricing.
Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH; sequence pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2). It was historically FDA-approved as Factrel (diagnostic GnRH stimulation test) and Lutrepulse (pulsatile IV pump for hypothalamic amenorrhea); both products are discontinued in the US. Gonadorelin remains on the FDA Category 1 bulk substances list and is widely compounded, most commonly as an off-label adjunct to TRT intended to preserve HPG-axis signaling.
Gonadorelin
Melanotan I
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Gonadorelin
Melanotan I
COA corpus from Disclosed Labs — independently tested batches only.
Gonadorelin
4
COAs
99.6%
Avg purity
2
Labs
Melanotan I
50
COAs
99.7%
Avg purity
12
Labs
The historical FDA-approved gonadorelin products (Factrel for diagnostic pituitary testing; Lutrepulse for pulsatile ovulation induction in hypothalamic amenorrhea) are discontinued commercially, but gonadorelin remains on the FDA Category 1 bulk substances list and is compounded under 503A/503B. Pulsatile pump delivery (every 60–120 minutes) is the clinical gold standard for hypothalamic amenorrhea and congenital hypogonadotropic hypogonadism, with systematic-review evidence supporting high ovulation rates (Tranoulis 2018, PMID 29605411) and faster spermatogenesis versus cyclical hCG/hMG in CHH men (Zhang 2018/2019, PMID 30569789; Büchter 1998, PMID 9758439). Use as a TRT adjunct in place of hCG is widespread in men's-health practice but is off-label and has limited dedicated controlled-trial data; its ability to maintain intratesticular testosterone once the HPG axis is fully suppressed by exogenous testosterone has not been rigorously established.
Key references
FDA-approved as Scenesse (Clinuvel, October 8, 2019) for increasing pain-free light exposure in adults with EPP, based on Phase III trials CUV039 and CUV040 showing more hours spent in sunlight without pain vs. placebo (Langendonk et al., NEJM, 2015; PMID 26132941). A randomized multicenter trial (Lim et al., JAMA Dermatology, 2015; PMID 25230094) also showed increased repigmentation when afamelanotide was combined with narrow-band UVB in vitiligo.
Key references
Gonadorelin (Hormone) and Melanotan I (Cosmetic) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs